Chronic Migraine Treatment Market Report 2024 (Global Edition)

Global Chronic Migraine Treatment Market Report 2024 Market Size Split by Type (Episodic, Migraine with Aura, Chronic, Others), by Treatment (Acute/Abortive Treatment, Preventive/prophylactic Treatmen...

Chronic Migraine Treatment Market Report Description

We have various report editions of Chronic Migraine Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Chronic Migraine Treatment Market Insights Video

Competitive Landscape of the Chronic Migraine Treatment Market

Key actors are prioritizing the maintenance of high-quality standards and gaining access to a large market size by leveraging their existing customer bases in the region. Brands that have already established a robust market presence may benefit from this approach. Furthermore, companies are making substantial investments in the advanced development of a novel therapeutic class of pharmaceuticals for the treatment of migraines.

In March 2024, Lilly has entered into a partnership with Amazon Pharmacy to offer home delivery of specific medications for the treatment of obesity, diabetes, and migraines. This collaboration has enabled patients to receive their medications in a timely and expedient manner, and they have access to clinical pharmacists who are available to provide support at all hours. This enhances patient care and medication management by capitalizing on Amazon's effective logistics. (Source: https://www.aboutamazon.com/news/retail/amazon-pharmacy-diabetes-migraine-medication-lillydirect) In September 2021, AbbVie has recently received FDA approval for QULIPTA™ (atogepant), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) that is specifically intended to prevent episodic migraine in adults. QULIPTA is an oral medication that can assist in the reduction of monthly migraine days by providing a once-daily dosage that delivers consistent and rapid results. AbbVie is proud to provide a comprehensive range of migraine treatment products, including preventive therapies for chronic and episodic migraines and an acute treatment for migraine attacks. This approval is supported by a clinical program that assessed the safety, tolerability, and efficacy of QULIPTA. (Source: https://news.abbvie.com/2021-09-28-FDA-Approves-QULIPTA-TM-atogepant-,-the-First-and-Only-Oral-CGRP-Receptor-Antagonist-Specifically-Developed-for-the-Preventive-Treatment-of-Migraine) In February 2022, ELYXYB™, the first FDA-approved, ready-to-use oral solution for acute migraine treatment in adults, has been introduced by BioDelivery Sciences International (BDSI). ELYXYB, which is composed of celecoxib, provides immediate and enduring relief without the need for premixing, shaking, or measuring. This launch represents BDSI's entry into the neurology market, thereby broadening their portfolio. The ELYXYB Passport Program guarantees patient access and assistance. The innovation and readiness to provide this critical treatment option were emphasized by BDSI's CEO, Jeff Bailey. The self-microemulsifying drug delivery system of ELYXYB improves solubility and absorption, rendering it a convenient and effective solution for migraine sufferers. (Source: https://www.biospace.com/biodelivery-sciences-international-announces-elyxyb-is-now-available-in-the-u-s-for-the-acute-treatment-of-migraine)

Top Companies Market Share in Chronic Migraine Treatment Industry: (In no particular order of Rank)

• Lundbeck Seattle BioPharmaceutical
• Eli Lilly and Company
• Amgen
• Novartis
• Allergan
• Teva Pharmaceuticals
• Biohaven Pharmaceuticals
• Biohaven Pharmaceuticals
• Dr. Reddy’s Labs
• AbbVie
• Impel NeuroPharma
• Zosano Pharma
• Aeon Biopharma Inc.
• Ionis Pharmaceuticals
• Inc.
• Charleston Laboratories.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Chronic Migraine Treatment Market

Which Region Dominates the Chronic Migraine Treatment Market in 2024?

According to Cognitive Market Research, North America currently dominates the Chronic Migraine Treatments market, and the region is expected to have significant growth during the projected period. The presence of numerous migraine awareness campaigns contributes to educating the public about the importance of timely and effective treatment, which drives the growth of the migraine treatment market in North America.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The regional governments are increasing their investments in healthcare infrastructure, ensuring improved access to medical facilities and treatments. People in many Asia Pacific countries are more willing to spend on advanced migraine treatments as their disposable income rises, driving market growth.

The current report Scope analyzes Chronic Migraine Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Chronic Migraine Treatment

According to Cognitive Market Research, the global Chronic Migraine Treatment market size was estimated at USD 3514.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1405.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Chronic Migraine Treatment market with a market size of USD 1109.18 million in 2024 and is anticipated to grow at a CAGR of 3.0% during the projected period. The migraine drug market in the United States is fueled by a large consumer base and a growing emphasis on developing quality of life through medical treatments.
• The Canada Chronic Migraine Treatment market had a market share of USD 168.70 million in 2024 and is anticipated to grow at a CAGR of 4.0% during the projected period. In Canada, advancements in healthcare infrastructure and the adoption of innovative migraine therapies are driving migraine drug market growth.
• The Mexico Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.7% during the projected period, with a market size of USD 127.93 million in 2024.

Europe Chronic Migraine Treatment

According to Cognitive Market Research, the global Chronic Migraine Treatment market size was estimated at USD 3514.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1054.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031.

• The United Kingdom Chronic Migraine Treatment market had a market share of USD 177.13 million in 2024 and is anticipated to grow at a CAGR of 4.3% during the projected period. The UK's well-developed healthcare system and wide range of medical services facilitate the effective distribution and availability of migraine treatments.
• The France Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 2.7% during the projected period, with a market size of USD 97.00 million in 2024.
• According to Cognitive Market Research, the German Chronic Migraine Treatment market size was valued at USD 208.76 million in 2024 and is anticipated to grow at a CAGR of 3.7% during the projected period. Germany's aging population and increased susceptibility to migraines drive demand for effective migraine treatments, which is aided by supportive healthcare policies.
• The Italy Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 2.9% during the projected period, with a market size of USD 90.67 million in 2024.
• The Russia Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 2.5% during the projected period, with a market size of USD 163.42 million in 2024.
• The Spain Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 2.6% during the projected period with a market size of USD 86.46 million in 2024
• The Luxembourg Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.6% during the projected period, with a market size of USD 32.68 million in 2024.
• The Portugal Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.3% during the projected period, with a market size of USD 22.14 million in 2024.
• The Greece Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.8% during the projected period, with a market size of USD 12.65 million in 2024.
• The Rest of Europe's Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 2.2% during the projected period, with a market size of USD 163.42 million in 2024.

Asia Pacific Chronic Migraine Treatment

According to Cognitive Market Research, the global Chronic Migraine Treatment market size was estimated at USD 3514.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 808.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Chronic Migraine Treatment market size was valued at USD 363.75 million in 2024 and is anticipated to grow at a CAGR of 6.5% during the projected period. China's migraine market is expanding due to changing lifestyles and a large population base, resulting in a significant public health focus on migraine treatment.
• The Japan Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 5.5% during the projected period, with a market size of USD 111.55 million in 2024.
• The India Chronic Migraine Treatment market had a market share of USD 97.00 million in 2024 and is anticipated to grow at a CAGR of 8.8% during the projected period. Rising awareness of migraine treatments in India, as well as increased healthcare spending, are key drivers of the migraine drugs market.
• The South Korean Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 6.1% during the projected period, with a market size of USD 80.83 million in 2024.
• The Australian Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 6.7% during the projected period, with a market size of USD 42.03 million in 2024.
• The South East Asia Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 8.0% during the projected period, with a market size of USD 55.78 million in 2024.
• The Rest of Asia Pacific Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 6.8% during the projected period, with a market size of USD 57.39 million in 2024.

South America Chronic Migraine Treatment

According to Cognitive Market Research, the global Chronic Migraine Treatment market size was estimated at USD 3514.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 175.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Chronic Migraine Treatment market size was valued at USD 75.21 million in 2024 and is anticipated to grow at a CAGR of 5.0% during the projected period. The migraine drugs market in Brazil is driven by a high awareness of migraines and treatment options, as well as increased government efforts to improve healthcare access.
• Argentina's Chronic Migraine Treatment market had a market share of USD 29.52 million in 2024 and is anticipated to grow at a CAGR of 5.3% during the projected period. In Argentina, improved healthcare infrastructure and a greater emphasis on diagnosing and treating migraines contribute to market expansion.
• Colombia Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 4.2% during the projected period, with a market size of USD 15.64 million in 2024.
• Peru Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 4.6% during the projected period, with a market size of USD 14.41 million in 2024.
• Chile Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 4.7% during the projected period, with a market size of USD 12.65 million in 2024.
• The Rest of Latin America's Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.5% during the projected period, with a market size of USD 28.29 million in 2024.

Middle East and Africa Chronic Migraine Treatment

According to Cognitive Market Research, the global Chronic Migraine Treatment market size was estimated at USD 3514.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 70.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031..

• The GCC Countries Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 5.5% during the projected period, with a market size of USD 30.08 million in 2024. In the GCC region, the availability of health insurance coverage for migraine treatments is a major motivator, increasing access to necessary medications.
• The Egypt Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 5.0% during the projected period, with a market size of USD 7.38 million in 2024.
• The South Africa Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 5.7% during the projected period, with a market size of USD 11.11 million in 2024. The increasing awareness of migraine treatments, as well as efforts to improve healthcare access and infrastructure, are driving South Africa's market growth.
• The Turkey Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 4.2% during the projected period, with a market size of USD 6.04 million in 2024.
• The Nigeria Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.8% during the projected period, with a market size of USD 7.38 million in 2024.
• The Rest of the MEA Chronic Migraine Treatment market is anticipated to see growth at a CAGR of 3.7% during the projected period, with a market size of USD 8.29 million in 2024.

Chronic Migraine Treatment Market Analysis

Chronic Migraine Treatment Market Type Segment Analysis

According to Cognitive Market Research, Episodic Chronic Migraine Treatments are likely to dominate the Chronic Migraine Treatment Market over the forecast period. Episodeic migraines are increasingly prevalent and afflict more individuals, hence acute attack alleviation solutions are in demand.

The Migraine with Aura is the fastest-growing segment in the Chronic Migraine Treatment Market, owing to greater awareness and diagnosis of this migraine type. Medical study and awareness have identified migraines with aura's unique symptoms and treatment demands, leading to tailored treatments and drugs. This has increased demand for effective therapies for this category, fueling its fast expansion.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Chronic Migraine Treatment Industry. Request a Free Sample PDF!

Chronic Migraine Treatment Market Treatment Segment Analysis

According to Cognitive Market Research, the Acute/Abortive Treatment segment holds the largest share of the market. Triptans and NSAIDs are among the medications and strategies that are intended to ameliorate the symptoms of a migraine attack included in this category. The dominance of this category is attributed to the immediacy of alleviation during attacks and the high prevalence of episodic migraines.

In the Chronic Migraine Treatment Market, the Preventive/prophylactic Treatment sector has been expanding at a rapid pace. Greater emphasis has been placed on preventive care as a result of the growing recognition of chronic migraines and their detrimental effects on quality of life. This category is experiencing accelerated development as a result of the increasing popularity of treatments such as CGRP inhibitors and other preventive medications, which are effective in reducing the frequency and severity of migraine attacks.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Chronic Migraine Treatment Route of Administration Segment Analysis

Chronic Migraine Treatment Market Route of Administration Segment Analysis

According to Cognitive Market Research, The Oral segment holds the largest market share. This is due to the widespread use of oral medications, including NSAIDs and triptans, due to their simplicity of administration, efficacy, and patient compliance.

In the Chronic Migraine Treatment market, the rapidly growing sector is the Parenteral category. The expansion of this category has been encouraged by the growing number of injectable treatments, including CGRP inhibitors, which are being developed and approved. These treatments are particularly advantageous for patients who do not respond favorably to oral medications and provide sudden relief.

• Oral
• Parenteral

Chronic Migraine Treatment Product Segment Analysis

Chronic Migraine Treatment Market Product Segment Analysis

According to Cognitive Market Research, the Prescription segment dominates the market, as a result of their effectiveness and the necessity of medical supervision in the treatment of severe and frequent migraine attacks. These medications, which require a prescription from a healthcare provider, are frequently more efficacious. Examples of such medications include CGRP inhibitors and triptans.

Over the Counter is projected to be the fastest-growing segment in the Chronic Migraine Treatment market. The rapid development of migraines has been facilitated by the increasing awareness and self-management of the condition, as well as the availability of effective over-the-counter options. The convenience and accessibility of over-the-counter medications for the relief of mild to moderate migraines are highly valued by consumers.

• Prescription
• Over The Counter

Chronic Migraine Treatment End User Segment Analysis

Chronic Migraine Treatment Market End User Segment Analysis

According to Cognitive Market Research, The Hospitals segment holds the largest market share. This is due to the fact that hospitals are the primary focus of care for patients with chronic migraines, as they provide comprehensive care that includes diagnosis, acute treatment, and preventive strategies.

In the Chronic Migraine Treatment market, the rapidly growing sector is the Homecare. The expansion of homecare for chronic migraine management has been facilitated by the development of portable and user-friendly treatment options, the availability of telemedicine, and the growing emphasis on patient convenience. This category has experienced accelerated growth as patients are now able to receive effective treatment in the privacy of their own residences.

• Hospitals
• Clinics
• Homecare

Chronic Migraine Treatment Distribution Channel Segment Analysis

Chronic Migraine Treatment Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the Hospital-Based Pharmacies segment dominates the market. This is due to the fact that hospitals are the primary focus of care for patients with chronic migraines, as they provide comprehensive care that includes diagnosis, emergency treatment, and preventive strategies.

Online Pharmacies is projected to be the fastest-growing segment in the Chronic Migraine Treatment market. The surge in online purchases of migraine medications has been facilitated by the convenience of online purchasing and the expanding penetration of e-commerce platforms. Consumers value the convenience of being able to compare prices, read reviews, and access a broader selection of products from the comfort of their residences.

• Hospital-Based Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion